BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74^th ACR Scientific Meeting being held in Atlanta, Georgia.

“Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout”

The data will be presented during a poster session scheduled for November 8, 2010 from 9:00-11:00 a.m. Eastern Time. The poster to be presented during the session is entitled:

• "Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout". This poster concludes that BCX4208 doses administered at 40, 80, 120, 160 and 240 mg once-daily monotherapy rapidly and significantly reduced serum uric acid (sUA) in patients with gout. BCX4208 was generally safe and well-tolerated at the doses evaluated in this study.